BrainStorm FY2022 net loss $24.3M; cash drops to $3M; FDA ADCOM for NurOwn BLA

BRAINSTORM CELL THERAPEUTICS INC.

Net loss of $24.3M ($0.66 per share) vs $24.5M ($0.68) in 2021; no revenue.
Cash and short-term deposits fell to $3M from $22M at year-end 2021.
R&D expenses $14M, G&A $10.9M; combined $24.9M operating spend.
FDA will hold Advisory Committee meeting to review NurOwn BLA for ALS; File over Protest used.
Dr. Stacy Lindborg promoted to Co-CEO in January 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. reported the fiscal year ended December 31, 2022 results: net income approximately $30.3 million.

Period: the fiscal year ended December 31, 2022
Net income: approximately $30.3 million
Result: reported results

Exact text from the filing

Net loss for the twelve months ended December 31, 2022, was approximately $

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-038729

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.